

Angelini Pharma launches crowdsourcing challenge to fund solutions to drug adherence and management of epilepsy

Challenge aims to significantly improve the lives of people with epilepsy, especially elderly and paediatric patients

LONDON, UNITED KINGDOM, July 2, 2024 /EINPresswire.com/ -- Angelini Pharma, part of the

“

Approximately one third of people living with epilepsy face difficulties with antiseizure medicine adherence and this is particularly challenging for elderly and paediatric populations.”

Rafal Kaminski, Chief Scientific Officer, Angelini Pharma

privately owned Angelini Industries, has launched a new crowdsourcing campaign to identify innovative new Drug Delivery Systems (DDS) and Treatment Approaches to significantly improve the lives of people with epilepsy, especially elderly and paediatric patients.

The challenge – [New Drug Delivery Systems and Treatments](#) for Improved Adherence and Better Management of Epilepsy – is the second partnership between Angelini Pharma and innovation scale-up [Wazoku](#) to identify innovative Drug Delivery Systems and Treatments. The challenge will tap into Wazoku's 700,000-strong network to identify how to improve already existing ASMs (Anti Seizures Medications), and to propose new DDS

and treatment approaches that utilise novel technologies.

Identifying new options to increase adherence is vital to the management of epilepsy, which affects 50 million people worldwide. While current epilepsy treatment options include approximately 30 antiseizure medications (ASMs) available in various pharmaceutical forms, there are limitations in terms of adherence and general management related to specific unmet needs such as age, comorbid conditions, and safety concerns.

“Approximately one third of people living with epilepsy face difficulties with antiseizure medicine adherence and this is particularly challenging for elderly and paediatric populations. Non-adherence can result in several serious consequences, including breakthrough seizures,²” said Rafal Kaminski, Chief Scientific Officer, Angelini Pharma. “This low adherence underscores the urgent need for more effective treatments that can better address the diverse needs of patients with epilepsy.”

Angelini Pharma researches, develops, and commercialises health solutions, focusing primarily on areas of brain health, including epilepsy. The company's first Open Innovation Challenge with Wazoku. focused on New Digital Approaches to Target Discovery in Epilepsy, and finished with 28 solutions received and four selected to be awarded.

Open Innovation has been a hugely successful way of driving innovative solutions in the pharmaceutical sector. It has been used to accelerate drug discovery and development and helps companies navigate challenges such as rising operational costs, product shortages, and the talent vacuum.

"Open innovation is being used more and more in the pharmaceutical sector and its potential to deliver solutions to challenges is vast," said Dino Ribic, Innovation Consultant, Wazoku. "We have already completed one successful campaign with Angelini Pharma and I await eagerly to see what is delivered this time."

The Wazoku Crowd is a 700,000-strong network of expert problem 'solvers', comprised of scientists, pharmacists, engineers, PhD students, CEOs, start-ups, and business leaders. It has a success rate of 80%+ in solving more than 2,500 challenges.

At least one cash prize of US\$25,000 is available for New Drug Delivery Systems and Treatments for Improved Adherence and Better Management of Epilepsy, based on theoretical evaluation of the written proposals by Angelini Pharma. The challenge closes on 26 August 2024.

-ends-

For further information about Wazoku, visit <https://www.wazoku.com>

For further information about Angelini Pharma, visit <https://www.angelinipharma.com/>

PR Contact: Wazoku Paul Allen – Rise PR + 44 (0) 7515 199 487 / paul@risepr.co.uk

Paul Allen

Rise PR

+ +44 7515 199487

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/724512791>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.